Clinical trials: sponsored by European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
This pro - and retrospective multicenter clinical epidemiological study studies the molecular genetic, host-derived and clinical determinants of glioblastoma patients with an overall survival of more than 5 years.
- Trial name
- NCT03770468
- Testing
- Blood drawl
- Where
- 27 sites in United States, Austria and 7 more
- Volunteers
- 599 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation
Chemo-free BRCA-targeted Neoadjuvant Strategy
This is a multicenter randomized phase ll clinical trial to evaluate the pathological complete response (pCR) in the tumour burden (primary and lymph nodes) with olaparib alone or in the olaparib and durvalumab arm in TNBC…
- Conditions
- TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
- Trial name
- NCT05209529
- Testing
- olaparib, Durvalumab
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
Trial assessing atezolizumab (anti-PD-L1) as treatment option for patients with mycosis fungoides/sezary syndrome having progressed under or after previous therapy For this study, we invite patients suffering from mycosis…
- Trial name
- PARCT (NCT03357224)
- Testing
- Atezolizumab
- Where
- 2 sites in Spain, Switzerland
- Volunteers
- 26 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Soft-tissue Sarcoma
A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
This is a multi-centre, open label, randomized phase 3 selection study (1:2:2 randomization). After confirmation of the eligibility criteria, 185 patients will be randomized 1:2:2 to either the control arm (doxorubicin 60-75…
- Trial name
- Tolerance (NCT04780464)
- Testing
- Doxorubicin, Cyclophosphamide Oral Product, Prednisolone
- Where
- 2 sites in Cyprus, Jordan
- Volunteers
- 14 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Dissecting the Pathways of Therapy Resistance in Early Breast Cancer
Within the 1st step MINDACT patients who have already relapsed will be asked to participate. For these patients a biopsy of the metastasis should have been taken.
- Trial name
- MINDACTRelapse (NCT04995575)
- Testing
- collection of the biopsy, blood samples
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 31 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Lymphoblastic Leukemia (ALL)
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
The main goal of this study is to improve the outcome of children and adolescents with standard risk (SR) first relapsed acute lymphoblastic leukemia.
- Trial name
- NCT01802814
- Testing
- SR-A + Epratuzumab, SR-B + Epratuzumab
- Where
- 17 sites in Australia, Austria and 15 more
- Volunteers
- 700 people
- Sponsor
- Charite University, Berlin, Germany
Colorectal Cancer, Colon Cancer Liver Metastasis
Diffusion-Weighted MRI for Liver Metastasis
The DREAM study will assess the diagnostic accuracy of diffusion-weighted MRI in combination with other imaging modalities (multiparametric MRI and CT Scan) in determining the true status of disappearing liver metastasis (DLM)…
- Conditions
- Colorectal Cancer, Colon Cancer Liver Metastasis, Malignant Neoplasm of Rectum Metastatic to Liver
- Trial name
- DREAM (NCT02781935)
- Testing
- DW-MRI
- Where
- 21 sites in United States, Austria and 3 more
- Volunteers
- 233 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Gastric and Esophagogastric Junction Adenocarcinoma
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma…
- Trial name
- VESTIGE (NCT03443856)
- Testing
- Nivolumab and Ipilimumab, chemotherapy
- Where
- 28 sites in Czechia, France and 7 more
- Volunteers
- 197 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Covid19, Patient Reported Outcome Measures, Quality of Life
Development of an International COVID-19 Specific Quality of Life Questionnaire, Phase III. The OSLO COVID-19 QLQ
Purpose: to develop an international validated patient-reported outcome measure for COVID-19 patients according to international guidelines.
- Trial name
- NCT04740372
- Testing
- No intervention. Method study. Psychometric testing
- Where
- Norway
- Volunteers
- 371 people
- Sponsor
- Oslo University Hospital
Fungal Infection, Leukemia
Empirical Versus Preemptive Antifungal Therapy
RATIONALE: Caspofungin acetate may be effective in treating fungal infections in patients with acute myeloid leukemia or myelodysplastic syndrome who are receiving treatment for their cancer.
- Conditions
- Fungal Infection, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT01288378
- Testing
- caspofungin acetate
- Where
- 16 sites in Belgium, Czechia and 4 more
- Volunteers
- 556 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Fallopian Tube Cancer, Ovarian Cancer
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT01402271
- Testing
- carboplatin, paclitaxel, pazopanib hydrochloride
- Where
- 9 sites in Belgium, Netherlands and 1 more
- Volunteers
- 88 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor
CREATE: Cross-tumoral Phase 2 With Crizotinib
The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways.
- Conditions
- Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma
- Trial name
- CREATE (NCT01524926)
- Testing
- Crizotinib (PF-02341066)
- Where
- 25 sites in Belgium, France and 8 more
- Volunteers
- 582 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Small Cell Lung Cancer (SCLC)
Pembrolizumab in Untreated Extensive SCLC
This is a multicenter, open-label, two armed, controlled, and randomized phase II trial investigating the activity of pembrolizumab in combination with standard chemotherapy in Extensive Disease (ED)-SCLC.
- Trial name
- REACTION (NCT02580994)
- Testing
- Pembrolizumab, cis/carboplatin and etoposide
- Where
- 18 sites in France, Italy and 1 more
- Volunteers
- 125 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer, Breast Cancer
An EORTC Study Updating the QLQ-BR23 to BR45
Female breast cancer is still the most frequent type of cancer in Europe with 21 per 100,000 women .The EORTC QLQ-BR23 was one of the first modules developed to be used in conjunction with the core questionnaire EORTC QLQ-C30 and…
- Trial name
- NCT04270123
- Testing
- EORTC QLQ-BR45 questionnaire
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Leeds
Cutaneous Melanoma
Minimal SN Tumor Burden
The purpose of this registry is to collect data in order to discover whether melanoma patients with minimal SN tumor burden should undergo a complete lymph node dissection (CLND) or not.
- Trial name
- Minitub (NCT01942603)
- Where
- 22 sites in Belgium, France and 8 more
- Volunteers
- 296 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma versus the current standard…
- Trial name
- COLUMBUS-AD (NCT05270044)
- Testing
- Encorafenib and Binimetinib
- Where
- 155 sites in Argentina, Australia and 21 more
- Volunteers
- 815 people
- Sponsor
- Pierre Fabre Medicament
Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB)
REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)
Adult patients with early stage MF-CTCL (stage IA-IB) will be eligible for this study. A total of 100 early stage MF-CTCL patients diagnosed in the past year will be enrolled.
- Trial name
- REACH (NCT04218825)
- Testing
- chlormethine gel
- Where
- 2 sites in France
- Volunteers
- 2 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Squamous Cell of Head and Neck
Biomarker-based Study in R/M SCCHN
This is a biomarker-driven trial that will enroll patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum-based chemotherapy.
- Trial name
- UPSTREAM (NCT03088059)
- Testing
- Afatinib, Palbociclib, standard of care
- Where
- 36 sites in Belgium, France and 3 more
- Volunteers
- 340 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Biliary Tract Cancer, Metastatic Cancer
Pembrolizumab in Biliary Tract Cancer
This is a single-arm, multi-centre, phase II study in biliary tract cancer (BTC) patients. The main objective is to detect an increase in progression-free survival rate at 6 months (according to RECIST version 1.1) from 60% in…
- Conditions
- Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer, Gallbladder Cancer
- Trial name
- NCT03260712
- Testing
- Pembrolizumab, Cisplatin, Gemcitabine
- Where
- 7 sites in Germany, Spain and 1 more
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- CATNON (NCT00626990)
- Testing
- temozolomide, DNA methylation analysis, laboratory biomarker analysis
- Where
- 132 sites in United States, Australia and 10 more
- Volunteers
- 751 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC